How Covered Entities and Pharma Companies Can Better Collaborate on Drug Discount Programs
Three things drug manufacturers and CEs can do to build trust and enable effective collaboration
Lower Health Care Costs, Help Inmates. Why Aren’t There PrEP Programs in Prison?
Prisons should offer abundant opportunities for HIV screening and comprehensive pre-exposure prophylaxis (PrEP) adherence programs to benefit incarcerated individuals and carceral systems as a whole.
At ViVE 2024, Panelists Share Prior Authorization Progress and Frustration in Payer Insights Program
At the Payer Insights sessions on Day 1 of ViVE 2024, a panel on prior authorization offered compelling insights from speakers who shared the positive developments in this area after years of mounting frustration. Speakers also shared challenges as they work with providers to figure out how policy developments and technology will work in practice.
340B Program Preserves, Improves Access to Rural Health Care
To ensure that rural hospitals like ours can continue delivering high-quality, comprehensive health care, the federal government must support and protect the 340B Drug Pricing Program that enables us to do what we do best.
Why Provider Groups Are Denouncing CMS’ New Payment Rules
CMS finalized updates to its physician fee schedule for 2024, as well as finalized the rule for next year’s Outpatient Prospective Payment System (OPPS). Provider groups are displeased with the updated rules, arguing that both physicians and provider organizations need more monetary relief than what the agency is offering.
Hospitals Have Concerns About CMS’ Proposed $9B Lump Sum Payment for Illegal 340B Cuts
CMS recently proposed a $9 billion lump sum payment to remedy illegal payment cuts for 340B drugs from 2018 to 2022. In general, hospital groups have reacted positively to the fact that 340B providers will receive lump sum payments but have expressed concern about CMS’ methods for maintaining budget neutrality with this plan.
CVS scheme diverted millions from underserved population, NY AG says
Attorney General Letitia James accused CVS of a scheme starting in 2017 to prevent New York safety net hospitals from using the company of their choice to obtain federal drug subsidies on prescriptions filled at CVS through the 340B program
When Investment Rhymes with Canada
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
Where Hillary & Co. have it wrong. Three reasons biopharmaceutical manufacturers are not the bogeymen many believe them to be.
The manufacturers seldom get credit for things they are doing right to the benefit to all concerned.
Is the healthcare industry tired of bashing the 340B drug pricing program?
Between 1.5 and 3 percent of all drug purchases made in America are made through 340B.